SCHEMBL784347

SCHEMBL784347

CC(C)n1cnc(C(N)=O)n1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA1 P30542 4/20 0.40
ADORA2A P29274 2/20 0.40
LMNA P02545 4/20 0.37
SMN1; SMN2 Q16637 2/20 0.37
ALDH1A1 P00352 2/20 0.37
GLA P06280 1/20 0.37
EIF4E P06730 1/20 0.37
CYP3A4 P08684 1/20 0.37
TOP1 P11387 1/20 0.37
TSHR P16473 1/20 0.37
THPO P40225 1/20 0.37
PMP22 Q01453 1/20 0.37
HTR2C P28335 1/20 0.35
HTR2B P41595 1/20 0.35
SLC6A3 Q01959 1/20 0.35
TMEM97 Q5BJF2 1/20 0.35
MAPK1 P28482 1/20 0.35
MGLL Q99685 1/20 0.32
ACHE P22303 2/20 0.32
IKBKB O14920 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18977796 0.84 LMNA (0.35) ADORA1ADORA2ALMNASMN1; SMN2ALDH1A1
SCHEMBL12924661 0.82 HCAR3 (0.36) ADORA1ADORA2ASMN1; SMN2ALDH1A1MGLL
SCHEMBL784212 0.82 ACHE (0.33) ADORA1ADORA2AALDH1A1MGLLACHE
SCHEMBL19861815 0.82 ACHE (0.38) ADORA1ADORA2ALMNASMN1; SMN2ALDH1A1
SCHEMBL10101242 0.81 PNP (0.42) ADORA1ADORA2A
SCHEMBL22399607 0.80 ACHE (0.40) ADORA1LMNASMN1; SMN2ALDH1A1GLA
SCHEMBL30587540 0.79 TDP1 (0.42) LMNAALDH1A1CYP3A4MAPK1POLB
SCHEMBL11851306 0.79 LMNA (0.35) ADORA1ADORA2ALMNASMN1; SMN2ALDH1A1
SCHEMBL30587581 0.79 TDP1 (0.42) LMNAALDH1A1CYP3A4MAPK1POLB
SCHEMBL12410700 0.78 NOTUM (0.46) ALDH1A1TMEM97MAPK1MGLL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 104 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240016820-A1 Lipid Disulfide Prodrugs and Uses Related Thereto UNIV EMORY (US) 2024-01-18 US disclosed
US-11840551-B2 Compositions and methods of modulating the immune response by activating alpha protein kinase 1 SHANGHAI YAO YUAN BIOTECHNOLOGY CO., LTD. (CN) 2023-12-12 US disclosed
US-11840551-B2 Compositions and methods of modulating the immune response by activating alpha protein kinase 1 SHANGHAI YAO YUAN BIOTECHNOLOGY CO., LTD. (CN) 2023-12-12 US disclosed
US-20230357168-A1 CARBOBICYCLIC NUCLEOSIDES FOR TREATMENT OF VIRAL INFECTION UNIV HONG KONG CHINESE (CN) 2023-11-09 US disclosed
US-20230357168-A1 CARBOBICYCLIC NUCLEOSIDES FOR TREATMENT OF VIRAL INFECTION UNIV HONG KONG CHINESE (CN) 2023-11-09 US disclosed
US-11801255-B2 Lipid disulfide prodrugs and uses related thereto EMORY UNIVERSITY (US) 2023-10-31 US disclosed
US-11773131-B2 Compositions and methods of modulating the immune response by activating alpha protein kinase 1 SHANGHAI YAO YUAN BIOTECHNOLOGY CO., LTD. (CN) 2023-10-03 US disclosed
US-11773132-B2 Cyclic di-nucleotides as stimulator of interferon genes modulators BEIJING XUANYI PHARMASCIENCES CO., LTD. (CN) 2023-10-03 US disclosed
US-11773132-B2 Cyclic di-nucleotides as stimulator of interferon genes modulators BEIJING XUANYI PHARMASCIENCES CO., LTD. (CN) 2023-10-03 US disclosed
US-11773131-B2 Compositions and methods of modulating the immune response by activating alpha protein kinase 1 SHANGHAI YAO YUAN BIOTECHNOLOGY CO., LTD. (CN) 2023-10-03 US disclosed
US-20100249068-A1 SUBSTITUTED NUCLEOSIDE AND NUCLEOTIDE ANALOGS ALIOS BIOPHARMA, INC. (US) 2010-09-30 US disclosed
US-20100249068-A1 SUBSTITUTED NUCLEOSIDE AND NUCLEOTIDE ANALOGS ALIOS BIOPHARMA, INC. (US) 2010-09-30 US disclosed
US-20100240604-A1 PROTECTED NUCLEOTIDE ANALOGS ALIOS BIOPHARMA, INC. (US) 2010-09-23 US disclosed
US-20100240604-A1 PROTECTED NUCLEOTIDE ANALOGS ALIOS BIOPHARMA, INC. (US) 2010-09-23 US disclosed
US-20100104532-A1 NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT GILEAD SCIENCES, INC. (US) 2010-04-29 US disclosed
US-20100074889-A1 4'-ALLENE-SUBSTITUTED NUCLEOSIDE DERIVATIVES ENANTA PHARMACEUTICALS, INC. 2010-03-25 US disclosed
US-20100074889-A1 4'-ALLENE-SUBSTITUTED NUCLEOSIDE DERIVATIVES ENANTA PHARMACEUTICALS, INC. 2010-03-25 US disclosed
US-20090197823-A1 ALISKIREN MODULATION OF NEUROGENESIS BRAINCELLS, INC. (US) 2009-08-06 US disclosed
US-20090197823-A1 ALISKIREN MODULATION OF NEUROGENESIS BRAINCELLS, INC. (US) 2009-08-06 US disclosed
US-20090176732-A1 PROTECTED NUCLEOTIDE ANALOGS ALIOS BIOPHARMA INC. (US) 2009-07-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090176732-A1 PROTECTED NUCLEOTIDE ANALOGS NTPCR, NT5C2, PNP ADORA1 92/4885ADORA2A 101/4885LMNA 777/4885
US-20090197823-A1 ALISKIREN MODULATION OF NEUROGENESIS DCX, NGF, BDNF ADORA1 1697/4885ADORA2A 1290/4885LMNA 2587/4885
US-20240016820-A1 Lipid Disulfide Prodrugs and Uses Related Thereto SMPD1, SGMS1, SGMS2 ADORA1 1043/4885ADORA2A 875/4885LMNA 3988/4885
US-20100074889-A1 4'-ALLENE-SUBSTITUTED NUCLEOSIDE DERIVATIVES CCNI, CCNA1, CDK1 ADORA1 144/4885ADORA2A 196/4885LMNA 1144/4885
US-20100104532-A1 NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT SLC29A1, NUDT1, EIF2AK2 ADORA1 199/4885ADORA2A 545/4885LMNA 2301/4885
US-11840551-B2 Compositions and methods of modulating the immune response by activating alpha protein kinase 1 PHKA1, PHKA2, PRKCA ADORA1 344/4885ADORA2A 368/4885LMNA 1674/4885
US-11801255-B2 Lipid disulfide prodrugs and uses related thereto SMPD1, SGMS1, GSTO1 ADORA1 1003/4885ADORA2A 822/4885LMNA 4099/4885
US-20100240604-A1 PROTECTED NUCLEOTIDE ANALOGS PNP, NTPCR, TYMP ADORA1 260/4885ADORA2A 213/4885LMNA 1360/4885
US-20230357168-A1 CARBOBICYCLIC NUCLEOSIDES FOR TREATMENT OF VIRAL INFECTION PNP, SLC29A1, SLC29A2 ADORA1 31/4885ADORA2A 11/4885LMNA 1571/4885
US-11773132-B2 Cyclic di-nucleotides as stimulator of interferon genes modulators STING1, IRF3, CGAS ADORA1 884/4885ADORA2A 216/4885LMNA 4707/4885
US-20100249068-A1 SUBSTITUTED NUCLEOSIDE AND NUCLEOTIDE ANALOGS PNP, TYMP, NTPCR ADORA1 170/4885ADORA2A 125/4885LMNA 1477/4885
US-11773131-B2 Compositions and methods of modulating the immune response by activating alpha protein kinase 1 PHKA1, PHKA2, PRKCA ADORA1 344/4885ADORA2A 368/4885LMNA 1674/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.